Masanori Nashi

Dr. Masanori Nashi

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1998 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
MNMasanori Nashi
Masanori Nashi
BMB. Manjunath
B. Manjunath
BBB. Banerjee
B. Banerjee
BMB.N. Muddu
B.N. Muddu

8 November 2022 in Journal of Dental Sciences
Verified
Journal Article
Open access
MNMasanori Nashi
Masanori Nashi
HKHiromitsu Kishimoto
Hiromitsu Kishimoto
MKMasaki Kobayashi
Masaki Kobayashi
ATAkira Tachibana
Akira Tachibana
MSMotoo Suematsu
Motoo Suematsu
TTToshihiko Takenobu
Toshihiko Takenobu
The incidence of medication-related osteonecrosis of the jaw is increasing worldwide, mostly due to the use of antiresorptive agents (ARAs) such as bisphosphonate (BP) and denosumab (Dmab). However, the proportion of BP-related osteonecrosis of the jaw (BRONJ) and Dmab-related osteonecrosis of the jaw (DRONJ) among all ARA-related osteonecrosis of the jaw (ARONJ) cases is not clear; this hinders appropriate treatment, recurrence-prevention planning, and avoidance of unnecessary Dmab withdrawal. Moreover, the causative drug administered at each disease stage remains unknown. Therefore, we conducted a retrospective study of patients with ARONJ who visited oral and maxillofacial surgery departments at hospitals in Hyogo Prefecture, Japan, over 3 years to classify and compare patient characteristics with those having BRONJ and DRONJ. We sought to identify the proportion of DRONJ in ARONJ. After excluding stage 0 patients, 1021 patients were included (471 high-dose; 560 low-dose). ARA treatment for bone metastases of malignant tumors and multiple myeloma was considered high dose, while that for cancer treatment-induced bone loss and osteoporosis was low dose. Low doses of BP and Dmab accounted for >50% patients; the results differed from those in other countries. DRONJ accounted for 58% and 35% of high-dose and low-dose cases, respectively. Stage 3 ARONJ cases comprised 92 (19.5%) low-dose BRONJ, 39 (20.1%) high-dose BRONJ, 24 (30%) low-dose DRONJ, and 68 (24.5%) high-dose DRONJ. Eighty-nine patients who received switch therapy were divided into BRONJ or DRONJ, but there was no difference in the ratio of each stage compared to the non-switch therapy. To the best of our knowledge, this is the first study to clarify the proportion of BRONJ and DRONJ cases, causative drug, and its doses by disease stages. DRONJ accounted for approximately 30% of the ARONJ, approximately 60% of which was due to high doses.

24 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
THToshinori Hirai
Toshinori Hirai
MNMasanori Nashi
Masanori Nashi
Candida spp. are common components of normal microbiota in the oral cavity. However, Candida albicans can be a primary cause of superficial infections in the oral cavity and esophagus, especially in immunocompromised individuals. While these infections are rarely life-threatening, they can significantly impair quality of life and, in severe cases, progress to hematogenous dissemination. Oral candidiasis often exhibits as pseudomembranous, erythematous (atrophic), chronic hyperplastic, denture stomatitis, or angular cheilitis. Esophageal candidiasis is typically diagnosed by upper endoscopy, which involves histological examination and brushing. Clinical guidelines recommend topical antifungal agents for mild oral candidiasis, and systemic agents for moderate-to-severe disease or when topical therapy fails. However, azole antifungals pose a substantial risk of drug–drug interactions, primarily due to the inhibition of cytochrome P450 enzymes and drug transporters, which dramatically alters the pharmacokinetics of co-administered drugs. Additionally, amphotericin B, a polyene macrolide antibiotic, may cause nephrotoxicity and electrolyte disturbances (e.g., hypokalemia and hypomagnesemia). Moreover, the co-administration of nephrotoxic drugs may augment the toxicity associated with amphotericin B. Therefore, this review aimed to provide a comprehensive overview of the management of oral and esophageal candidiasis from the viewpoint of clinical pharmacology, with a particular focus on drug–drug interactions and adverse effect profiles.

27 September 2022 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
MNMasanori Nashi
Masanori Nashi
THToshinori Hirai
Toshinori Hirai
TITakuya Iwamoto
Takuya Iwamoto
TTToshihiko Takenobu
Toshihiko Takenobu

28 September 2021 in Journal of Dental Sciences
Verified
Journal Article
Open access
KMKeigo Maeda
Keigo Maeda
YHYuzo Hirai
Yuzo Hirai
MNMasanori Nashi
Masanori Nashi
SYShinsuke Yamamoto
Shinsuke Yamamoto
NTNaoki Taniike
Naoki Taniike
TTToshihiko Takenobu
Toshihiko Takenobu
The epidemiology of infective endocarditis (IE) is under constant change due to the aging society and increases in antimicrobial-resistant pathogens. However, IE remains severe. This study aimed to review the current clinical characteristics of IE and the antimicrobial susceptibility of oral bacteria (OB) isolated from blood cultures to implement appropriate antimicrobial prophylaxis. We retrospectively investigated the clinical features of 180 patients with IE in whom OB and pathogens except OB (eOB) were identified as causative microorganisms via blood cultures. The susceptibility of the OB group to eight antibiotics was examined by broth microdilution. Among causative microorganisms, the isolation rate of staphylococci was slightly higher than that of OB; however, the difference was not significant (36.7% vs. 33.8%, p = 0.3203). The number of patients with underlying cardiac disease was significantly higher in the OB group than in the eOB group (53.7% vs. 34.1%, p = 0.0113). Only one ampicillin-resistant OB was detected (2.0%). OBs were significantly less susceptible to clarithromycin and azithromycin than to ampicillin (98.0% vs. 66.7% and 98.0% vs. 60.0%, p = 0.0003 and p = 0.0003, respectively). Moreover, OBs were significantly less susceptible to clarithromycin and azithromycin than to clindamycin (66.7% vs. 88.2% and 60.0% vs. 88.2%, p = 0.0301 and p = 0.0217, respectively). OBs were susceptible to ampicillin. However, the susceptibility of OBs to clarithromycin and azithromycin was significantly lower than that to ampicillin and clindamycin. These results are important and should help decisions regarding guide antimicrobial prophylaxis.

1 July 2020 in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Verified
Journal Article
Closed access
KMKeigo Maeda
Keigo Maeda
SYShinsuke Yamamoto
Shinsuke Yamamoto
MNMasanori Nashi
Masanori Nashi
YMYumika Mukainaka
Yumika Mukainaka
NTNaoki Taniike
Naoki Taniike
TTToshihiko Takenobu
Toshihiko Takenobu